IDEXX Laboratories, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IX1.F | LH | 4544.T | ICLR | EYWN.F | TMO | |
|---|---|---|---|---|---|---|
| Market cap | 48.55B | 29.86B | 217.00B | 15.22B | 11.46B | 261.64B |
| P/E (TTM) | 47.8 | 30.1 | 23.5 | 81.2 | 25.0 | 37.2 |
| Forward P/E | 65.7 | 18.8 | 39.3 | 17.5 | — | 25.4 |
| Price/book | 29.2 | 3.4 | 1.6 | 1.7 | 2.7 | 4.8 |
| Dividend yield | — | 0.78% | 3.22% | — | 1.09% | 0.27% |
| 1-year change | −4.00% | +49.12% | −0.56% | +26.94% | −12.44% | +24.77% |
| Today | +3.88% | +3.92% | +3.51% | −0.32% | +3.23% | +1.12% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All IX1.F news ›IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)
IDEXX Laboratories lifts FY26 revenue guidance after strong Q3 results. Read here for a detailed investment analysis of IDXX stock. - IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward…
IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class
IDEXX Laboratories has best-in-class diagnostics, high recurring revenue, and a robust innovation pipeline. Find out why IDXX stock is a buy. - IDEXX Laboratories delivered strong Q3 results, beating expectations with 9.86% organic revenue…
Morgan Stanley maintains IDEXX Laboratories at Overweight, raises price target to $810 from $805
Morgan Stanley maintained IDEXX Laboratories at Overweight and raised its price target to $810 from $805, a 0.6% increase. The price target implies an upside of 20.6% from the Nov 2 close of $671.64. Recent analyst actions on IDEXX…
IDEXX Laboratories surges 22% on Q3 beat, raised outlook
(IDXX:NASDAQ) Seeking Alpha SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication. aluxum/E+ via Getty Images Shares of IDEXX Laboratories (IDXX), a developer…
IDEXX Laboratories Q3 2026: EPS Beats by 8%, Guidance Raised
As seen on the 24/7 Wall St. homepage on November 2, 2026. IDEXX Laboratories posted Q3 2026 GAAP EPS of $4.01, beating expectations and extending its streak of beating consensus EPS to seven consecutive quarters. CAG Diagnostics recurring…
IDEXX Laboratories 3Q 2026: Revenue $1.21B, Net income $317.15M, EPS $4.01— 10-Q Summary
TradingView IDEXX Laboratories 3Q 2026: Revenue $1.21B, Net income $317.15M, EPS $4.01— 10-Q Summary IDEXX Laboratories reported third-quarter 2026 revenue of $1.21 billion, up 9.9% year over year, while net in
IDEXX Laboratories Inc IX1
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in…
IDEXX Laboratories Drops 5.6% in a Single Session, Shedding $2.4 Billion
As seen on the 24/7 Wall St. homepage on October 30, 2026. A 5.63% intraday slide to $550.91 strips roughly $2.4 billion off a $43.4 billion veterinary-diagnostics name that rarely moves this hard in a single session. Watch whether it…
IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?
IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report its earnings on Monday, November 2, 2026. The company has a market value of about $45.5 billion. Over the last twelve months it generated $4.6 billion in revenue and $1.5 billion in…
IDEXX Laboratories, Inc. $IDXX Shares Purchased by Citizens Financial Group Inc. RI
Citizens Financial Group Inc. RI grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 51.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com38
- seekingalpha.com7
- themarketsdaily.com3
- 247wallst.com2
- defenseworld.net2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 60 articles, not a forecast.